A generic heart drug made by Impax Laboratories Inc. and two other companies is at the center of an investigation by the Connecticut attorney general’s office over a spike in price.
The inquiry, which revolves around the drug generically known as digoxin, is focused on two areas. Authorities will probe if the drug’s price was fixed or if the company violated state antitrust laws by dividing customers or territories for digoxin sales, Hayward-based Impax (NASDAQ: IPXL) said Tuesday.
Help employers find you! Check out all the jobs and post your resume.
